Biotransformation and in vivo stability of protein biotherapeutics: Impact on candidate selection and pharmacokinetic profiling

Drug Metabolism and Disposition

Volumn 42, Issue 11, 2014, Pages 1873-1880

  Hall, Michael P ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; CALICHEAMICIN; CYTOKINE; DENOSUMAB; FIBROBLAST GROWTH FACTOR 21; FILGRASTIM; GLUCAGON LIKE PEPTIDE 1; GROWTH FACTOR; MONOCLONAL ANTIBODY; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROTEIN; RECOMBINANT ERYTHROPOIETIN; ROMIPLOSTIM; STROMAL CELL DERIVED FACTOR 1; BIOLOGICAL PRODUCT;

BIOTRANSFORMATION; CONJUGATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY FAILURE; MASS SPECTROMETRY; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NEOPLASM; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; RECEPTOR BINDING ASSAY; SHORT SURVEY; URINARY EXCRETION; ANIMAL;

ANIMALS; BIOLOGICAL PRODUCTS; BIOTRANSFORMATION; HUMANS; PROTEINS;

EID: 84926311802     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058347     Document Type: Short Survey

References (77)

1. Ackermann BL and Berna MJ (2007) Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics 4:175-186.
2. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, Springer DL, and Pounds JG (2002) Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 1:947-955.
3. Ahmed FE (2008) Utility of mass spectrometry for proteome analysis: part I. Conceptual and experimental approaches. Expert Rev Proteomics 5:841-864.
4. Antonsson B, De Lys P, Dechavanne V, Chevalet L, and Boschert U (2010) In vivo processing of CXCL12a/SDF-1a after intravenous and subcutaneous administration to mice. Proteomics 10:4342-4351.
5. Baillie TA (2008) Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 21:129-137.
6. Behrens CR and Liu B (2014) Methods for site-specific drug conjugation to antibodies. MAbs 6:46-53.
7. Boghaert ER, Sridharan L, Armellino DC, Khandke KM, DiJoseph JF, Kunz A, Dougher MM, Jiang F, Kalyandrug LB, and Hamann PR, et al. (2004) Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Clin Cancer Res 10:4538-4549.
8. Boulanger L, Roughly P, and Gaudreau P (1992) Catabolism of rat growth hormone-releasing factor(1-29) amide in rat serum and liver. Peptides 13:681-689.
9. Bronsema KJ, Bischoff R, and van de Merbel NC (2012) Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 893-894:1-14.
10. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, and Williams G, et al. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490-1496.
11. Cai B, Pan H, and Flynn GC (2011) C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo. Biotechnol Bioeng 108:404-412.
12. Charman SA, Segrave AM, Edwards GA, and Porter CJ (2000) Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J Pharm Sci 89:168-177.
13. Claus TH, Pan CQ, Buxton JM, Yang L, Reynolds JC, Barucci N, Burns M, Ortiz AA, Roczniak S, and Livingston JN, et al. (2007) Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. J Endocrinol 192:371-380.
14. Correia IR (2010) Stability of IgG isotypes in serum. MAbs 2:221-232.
15. Dai S, Song H, Dou G, Qian X, Zhang Y, Cai Y, Liu X, and Tang Z (2005) Quantification of sifuvirtide in monkey plasma by an on-line solid-phase extraction procedure combined with liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 19:1273-1282.
16. D'Amour P and Brossard JH (2005) Carboxyl-terminal parathyroid hormone fragments: role in parathyroid hormone physiopathology. Curr Opin Nephrol Hypertens 14:330-336.
17. Deacon CF (2004) Circulation and degradation of GIP and GLP-1. Horm Metab Res 36:761-765.
18. Deng R, Jin F, Prabhu S, and Iyer S (2012) Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 8:141-160.
19. Domon B and Aebersold R (2006) Mass spectrometry and protein analysis. Science 312:212-217.
20. Duan X, Dai L, Chen S-C, Balthasar JP, and Qu J (2012) Nano-scale liquid chromatography/mass spectrometry and on-the-fly orthogonal array optimization for quantification of therapeutic monoclonal antibodies and the application in preclinical analysis. J Chromatogr A 1251:63-73.
21. Dubois M, Becher F, Herbet A, and Ezan E (2007) Immuno-mass spectrometry assay of EPI-HNE4, a recombinant protein inhibitor of human elastase. Rapid Commun Mass Spectrom 21:352-358.
22. Dubois M, Fenaille F, Clement G, Lechmann M, Tabet J-C, Ezan E, and Becher F (2008) Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal Chem 80:1737-1745.
23. Ens W and Standing KG (2005) Hybrid quadrupole/time-of-flight mass spectrometers for analysis of biomolecules. Methods Enzymol 402:49-78.
24. Ezan E, Dubois M, and Becher F (2009) Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst (Lond) 134:825-834.
25. Favre-Kontula L, Johnson Z, Steinhoff T, Frauenschuh A, Vilbois F, and Proudfoot AE (2006) Quantitative detection of therapeutic proteins and their metabolites in serum using antibody-coupled ProteinChip Arrays and SELDI-TOF-MS. J Immunol Methods 317:152-162.
26. Fredholt K, Adrian C, Just L, Hoj Larsen D, Weng S, Moss B, and Juel Friis G (2000) Chemical and enzymatic stability as well as transport properties of a Leu-enkephalin analogue and ester prodrugs thereof. J Control Release 63:261-273.
27. Hager T, Spahr C, Xu J, Salimi-Moosavi H, and Hall M (2013) Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal Chem 85:2731-2738.
28. Hall MP, Gegg C, Walker K, Spahr C, Ortiz R, Patel V, Yu S, Zhang L, Lu H, and DeSilva B, et al. (2010) Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J 12:576-585.
29. Hamuro LL and Kishnani NS (2012) Metabolism of biologics: biotherapeutic proteins. Bioanalysis 4:189-195.
30. Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T, Yie J, Wang W, Winters D, and Smith S, et al. (2012) Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS ONE 7:e49345.
31. Heudi O, Barteau S, Zimmer D, Schmidt J, Bill K, Lehmann N, Bauer C, and Kretz O (2008) Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal Chem 80:4200-4207.
32. Hill H (2010) Selectivity of ligand-binding assays in relationship to the measurement of biologics: how much does it matter? Bioanalysis 2:1525-1530.
33. Hussain A, Gorovits B, Leal M, and Fluhler E (2014) PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability. Bioanalysis 6:21-32.
34. Ji QC, Rodila R, Gage EM, and El-Shourbagy TA (2003) A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein. Anal Chem 75:7008-7014.
35. Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, Zaratin P, Carbonatto M, Mack M, Smailbegovic A, and Rose M, et al. (2004) Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 173:5776-5785.
36. Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 22:868-876.
37. Kuang B, King L, and Wang HF (2010) Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2:1125-1140.
38. Li H, Ortiz R, Tran L, Hall M, Spahr C, Walker K, Laudemann J, Miller S, Salimi-Moosavi H, and Lee JW (2012) General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal Chem 84:1267-1273.
39. Liao S, Qie JK, Xue M, Zhang ZQ, Liu KL, and Ruan JX (2010) Metabolic stability of human parathyroid hormone peptide hPTH (1-34) in rat tissue homogenates: kinetics and products of proteolytic degradation. Amino Acids 38:1595-1605.
40. Lin JH (2009) Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab 10:661-691.
41. Liu YD, Goetze AM, Bass RB, and Flynn GC (2011a) N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies. J Biol Chem 286:11211-11217.
42. Liu H, Manuilov AV, Chumsae C, Babineau ML, and Tarcsa E (2011b) Quantitation of a recombinant monoclonal antibody in monkey serum by liquid chromatography-mass spectrometry. Anal Biochem 414:147-153.
43. Liu YD, van Enk JZ, and Flynn GC (2009) Human antibody Fc deamidation in vivo. Biologicals 37:313-322.
44. Lobo ED, Hansen RJ, and Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668.
45. Lopez MF, Rezai T, Sarracino DA, Prakash A, Krastins B, Athanas M, Singh RJ, Barnidge DR, Oran P, and Borges C, et al. (2010) Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 56:281-290.
46. Lu Q, Zheng X, McIntosh T, Davis H, Nemeth JF, Pendley C, Wu SL, and Hancock WS (2009) Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Anal Chem 81:8715-8723.
47. MacNeill R, Stromeyer R, Urbanowicz B, Acharya V, and Moussallie M (2013) LC-MS/MS quantification of parathyroid hormone fragment 1-34 in human plasma. Bioanalysis 5:415-422.
48. Mann M, Hendrickson RC, and Pandey A (2001) Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem 70:437-473.
49. McLennan DN, Porter CJH, Edwards GA, Martin SW, Heatherington AC, and Charman SA (2005) Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep. J Pharmacol Exp Ther 313:345-351.
50. Molineux G and Newland A (2010) Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 150:9-20.
51. Murphy RE, Kinhikar AG, Shields MJ, Del Rosario J, Preston R, Levin N, and Ward GH (2010) Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples. J Pharm Biomed Anal 53:221-227.
52. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, and Genant HK, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
53. Nolting B (2013) Linker technologies for antibody-drug conjugates. Methods Mol Biol 1045:71-100.
54. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, and Eddes JS, et al. (2005) Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5:3226-3245.
55. Pan CQ, Buxton JM, Yung SL, Tom I, Yang L, Chen H, MacDougall M, Bell A, Claus TH, and Clairmont KB, et al. (2006) Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem 281:12506-12515.
56. Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, and Borzilleri RM (2013) Antibody-drug conjugates: current status and future directions. Drug Discov Today (Nov):15 [Epub ahead of print].
57. Powell MF, Grey H, Gaeta F, Sette A, and Colón S (1992) Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharm Sci 81:731-735.
58. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpé S, and Van Damme J (1998) Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 273:7222-7227.
59. Prueksaritanont T and Tang C (2012) ADME of biologics-what have we learned from small molecules? AAPS J 14:410-419.
60. Quattrocchi E and Kourlas H (2004) Teriparatide: a review. Clin Ther 26:841-854.
61. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, Mehigh RJ, Cockrill SL, Scott GB, and Tammen H, et al. (2005) HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5:3262-3277.
62. Rai AJ and Vitzthum F (2006) Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 3:409-426.
63. Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4:413-415.
64. Roopenian DC and Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725.
65. Schall TJ, Bacon K, Toy KJ, and Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347:669-671.
66. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, and Mai E, et al. (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30:184-189.
67. Siskos AP, Katsila T, Balafas E, Kostomitsopoulos N, and Tamvakopoulos C (2009) Simultaneous absolute quantification of the glucose-dependent insulinotropic polypeptides GIP1-42 and GIP3-42 in mouse plasma by LC/ESI-MS/MS: preclinical evaluation of DP-IV inhibitors. J Proteome Res 8:3487-3496.
68. Sofianos ZD, Katsila T, Kostomitsopoulos N, Balafas V, Matsoukas J, Tselios T, and Tamvakopoulos C (2008) In vivo evaluation and in vitro metabolism of leuprolide in mice - mass spectrometry-based biomarker measurement for efficacy and toxicity. J Mass Spectrom 43:1381-1392.
69. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, and Yamaguchi T (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184:1968-1976.
70. Tabrizi MA, Tseng CM, and Roskos LK (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11:81-88.
71. Tammen H (2008) Specimen collection and handling: standardization of blood sample collection. Methods Mol Biol 428:35-42.
72. Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, Phuong T, Barnett R, Hehli B, and Song F, et al. (2014) A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci USA 111:1766-1771.
73. Tipton JD, Tran JC, Catherman AD, Ahlf DR, Durbin KR, and Kelleher NL (2011) Analysis of intact protein isoforms by mass spectrometry. J Biol Chem 286:25451-25458.
74. Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 9:269-277.
75. Walsh G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917-924.
76. Wang W, Chen N, Shen X, Cunningham P, Fauty S, Michel K, Wang B, Hong X, Adreani C, and Nunes CN, et al. (2012) Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos 40:952-962.
77. Werle M and Bernkop-Schnürch A (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351-367.